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ABSTRACT
BACKGROUND AND PURPOSE: Biallelic constitutional mutations in DNA mismatch repair genes cause a distinct syndrome, consti-
tutional mismatch repair deficiency syndrome (CMMRD), characterized by cancers from multiple organs, most commonly brain
tumors, during childhood. Surveillance protocols include total and brain MR imaging among other modalities to enable early
detection of tumors. Brain surveillance scans revealed prominent brain developmental venous anomalies (DVAs) in some patients.
DVAs are benign vascular anomalies, and their incidence in the general population is 2.6%– 6.4%. Most developmental venous
anomalies are asymptomatic and are found incidentally. Our purpose was to assess the prevalence of DVAs in CMMRD patients and
describe their phenotype.
MATERIALS AND METHODS: A retrospective descriptive analysis of brain MR imaging studies from 10 patients from 3 families with
CMMRD was performed. Analysis included the number of developmental venous anomalies, location, draining vessels, and associated
vascular anomalies (ie, cavernomas), with clinical correlation of symptoms and tumors.
RESULTS: All 10 patients had 2 developmental venous anomalies, and 2 had, in addition, non-therapy-induced cavernomas. There was no
clinically symptomatic intracranial bleeding from developmental venous anomalies. Six patients had malignant brain tumors. The location
of brain tumors was not adjacent to the developmental venous anomalies. No new developmental venous anomalies developed during
follow-up.
CONCLUSIONS: The occurrence of multiple developmental venous anomalies in all our patients with CMMRD suggests that develop-
mental venous anomalies may be a characteristic of this syndrome that has not been previously described. If confirmed, this quantifiable
feature can be added to the current scoring system and could result in early implementation of genetic testing and surveillance protocols,
which can be life-saving for these patients.
ABBREVIATIONS: CMMRD  constitutional mismatch repair deficiency syndrome; DVA  developmental venous anomaly
Constitutional mismatch repair deficiency syndrome(CMMRD) is a cancer-predisposition syndrome character-
ized mainly by a high risk for developing cancer in childhood and
young adulthood as well as nonmalignant features. The most
common malignancies are brain tumors (predominantly malig-
nant gliomas, though other tumors are reported), lymphoid
malignancies (most commonly non-Hodgkins lymphomas and
leukemia), and gastrointestinal cancers (Lynch syndrome–associ-
ated tumors, especially colorectal cancer).1,2 Nonmalignant man-
ifestations of the syndrome include benign tumors such as adeno-
mas and neurofibromas, features of neurofibromatosis type 1,
predominantly café au lait macules, other hypo- and hyperpig-
mented skin alterations, pilomatricomas, and other features that
were included in the suggested diagnostic criteria by the European
Consortium.1
Because CMMRD is a cancer-predisposition syndrome with a
very high penetrance and most reported individuals are affected
during childhood, surveillance protocols were developed aiming
at early detection and interventions of these cancers. MR imaging
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of the brain, every 6 months, starting at diagnosis or birth, is part
of the surveillance protocol recommended for these children by
the European Consortium Care for CMMR-D3 and the Interna-
tional Biallelic Mismatch Repair Deficiency Consortium.2,4 It is
important to arrive at a definite diagnosis of CMMRD in a pedi-
atric or young adult patient with cancer as early as possible to
allow the recommended surveillance for the patient and genetic
counseling for family members. To facilitate CMMRD testing
in patients with cancer, the European Consortium Care for
CMMR-D suggested a score based on diagnostic criteria.1 In the
suggested score, several features of the syndrome are assigned
points; a patient with a 3-point score or above is referred for
genetic counseling. In Tel Aviv Sourasky medical center, we noted
prominent developmental venous anomalies (DVAs) on routine
brain MR imaging performed as a part of our surveillance proto-
col in patients with CMMRD.
DVA is the most frequently encountered cerebral vascular
malformation, with an incidence of 2.6%– 6.4% in different stud-
ies.5,6 A DVA is characterized by a cluster of venous radicles that
converge into a collecting vein, resulting in the typical caput me-
dusa appearance of the DVA.7 The collecting vein crosses a vari-
able length of brain parenchyma to join either the superficial or
deep venous system. Two or more DVAs coexisting in separate
regions of the brain were observed in 7%–16% of described pa-
tients with DVAs.8,9 Most DVAs are asymptomatic and are found
incidentally. However, DVAs have been documented as a rare
cause of cerebrovascular bleeding and ischemic events.7 There is a
known association between DVAs and cavernomas.6,7
Our aim was to assess the prevalence of DVAs in children with
CMMRD and to describe their phenotype to elucidate possible
distinct features associated with CMMRD.
MATERIALS AND METHODS
We performed detailed clinical and imaging analysis of all chil-
dren from 3 different families that are carriers of DNA mismatch
repair genes, each family with a distinct type of mutation. The first
family has a PMS2 mutation (c.2458dupA), with 5 affected ho-
mozygous members. The second family has a MSH6 mutation
[c.2314cT (p.Arg772Trp)], with 2 affected homozygous mem-
bers. The third family has 2 different pathogenic mutations in
MSH6 (c.3984_3987dupGTCA//c.3959_3962delCAAG), with 3
affected members who are compound heterozygotes.
All children had surveillance brain MR imaging during the
past 10 years. This retrospective study was approved by Tel Aviv
Sourasky medical center institutional review board. A retrospec-
tive descriptive analysis of their brain MR imaging studies in-
cluded the number of DVAs, location, draining vessels (periph-
eral or central), length and diameter of the collecting vein,
associated parenchymal changes (as reflected by increased T2WI
signal intensity), and the presence of associated cavernomas. Cor-
relation with coexisting brain tumor presence and location was
also performed. Descriptive statistics were performed with SPSS
(IBM, Armonk, New York).
RESULTS
Brain MR imaging studies of 10 children with CMMRD were
evaluated. The complete patient information is presented in the
On-line Table. There were 6 boys and 4 girls. The age at the earliest
study available per child ranged from 1.0 to 12.0 years (mean, 6.5
years). Seven children were treated for CNS tumors (4 glioblas-
toma multiforme, 1 medulloblastoma, 1 gliomatosis cerebri, and
1 cord primitive neuroectodermal tumor), 1 child was treated for
acute myeloid leukemia (AML), and 2 children were treated for
lymphoma. Colon polyposis was present in 6 children, and ade-
nocarcinoma of the colon, in 1 child. DVAs were noted in all
children, constituting 100% prevalence. Five children had 2
DVAs, 1 child had 3 DVAs (Fig 1), 3 children had 5 DVAs, and 1
child had 7 DVAs. In total, 35 DVAs were observed; 83% were in
the supratentorial brain and 64% drained to peripheral cortical
veins. The diameters of the collecting veins ranged from a mini-
mum of 0.8 mm to a maximum of 3.0 mm (average, 1.9 mm;
median, 1.8 mm; mode, 2.2 mm). The length of the collecting vein
ranged from a minimum of 5.0 mm to a maximum of 39.0 mm
(average, 24.9 mm; median, 27.0 mm; mode, 30.0 mm). There
were T2 signal changes in the brain parenchyma adjacent to the
DVA in 26% of DVAs (Fig 2).
In children with brain tumors, there was no correlation be-
tween the tumor locations and the location of the DVA. Caverno-
mas were present in 2 patients. One patient with a brain tumor
had a single small cavernoma adjacent to the DVA before therapy;
on follow-up studies, after tumor treatment with radiation ther-
apy, he developed focal bleeding in the known cavernoma and
bleeding in additional therapy-induced multiple cavernomas that
were not apparent on the initial study. A second patient had 2
non-therapy-induced cavernomas present but distant from the
DVA. For 9 children, follow-up studies were available; the time
between first and last available studies ranged from 0.2 to 7.5
years, and there was no change in the number of DVAs on fol-
low-up studies.
DISCUSSION
In this study, we observed 100% prevalence of multiple DVAs in
children with CMMRD. This is strikingly different from the prev-
alence of DVAs in the healthy population, which was reported as
2.7% in a study based on postmortem evaluation,5 and 6.4% in a
more recent study based on modern MR imaging.6 Gökçe et al6
evaluated 1165 patients with brain MR imaging studies and found
DVAs in 75 patients; of those, 10 had multiple DVAs, which is
0.9% of their total evaluated population and 13.3% of the group
of patients who had DVAs. The phenotypic characteristics of the
DVAs in their study included 73% supratentorial location, 50%
drainage to peripheral veins, and a collecting vein diameter range
of 1.0 – 4.3 mm (median, 2.0 mm). These findings are not signif-
icantly different from ours with 83% supratentorial location, 64%
drainage to peripheral veins, and a collecting vein diameter range
of 0.8 –3.0 mm (median, 1.8 mm). We found associated T2 signal
changes in the parenchyma adjacent to the DVA in 26% of the
DVAs, which is within the range of those reported in different
studies: 7.8%,10 11.6%,8 and 28%.11 The phenotypic similarities
of the DVAs in our study group compared with those reported in
the general population exclude morphologic unique features of
this vascular malformation in CMMRD patients.
An increased prevalence of DVAs was reported in association
with extensive head and neck venolymphatic malformations. In a
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series of 40 patients with facial venous malformations, 20% had
associated DVAs and 12.5% had multiple DVAs.12 In a series of 33
patients with orbital and periorbital lymphatic or venolymphatic
malformations, up to 60% of patients had associated DVAs.13 We
did not encounter associated head and neck vascular malforma-
tions in our study population, and we did not find an association
between CMMRD and vascular malformations in the literature. It
has been suggested that DVAs may be part of intracranial mani-
festations of neurocutaneous disorders because there are case re-
ports describing an association between DVAs and blue rubber
bleb nevus syndrome.14,15 Patients with CMMRD have not been
reported to have any association with blue rubber bleb nevus syn-
drome, but there is a known phenotypic overlap with neurofibro-
matosis type 1, most commonly café-au-lait macules.16 However,
there are no known reports describing the prevalence of DVAs in
patients with neurofibromatosis type 1. From our experience (un-
published data), the prevalence of DVAs in the neurofibromatosis
type 1 population is not as high as that seen in this study. Baas et
al17 reported an association between corpus callosum agenesis,
gray matter heterotopia, and CMMRD;
these findings were not present in our
study group.
Jones et al18 reported an increased
prevalence of DVAs in a population of
patients with primary brain tumors
compared with the healthy population;
in their study, 10.2% of patients with
brain tumors had a DVA present com-
pared with 5.3% of the control group.
Among patients with DVAs, only 4 had
1 DVA. They did not find any correla-
tion between the tumor and DVA loca-
tions, which is consistent with our re-
sults of no correlation between tumor
site and DVA location. In their study,
they did not mention whether children
with CMMRD were included among
the patients with brain tumors. Among
studies describing patients with CM-
MRD, in a French cohort of 31 pa-
tients,19 there was mention of only 2
patients with intracranial angiomas;
assuming the term “angioma” repre-
sents a DVA, this finding is very differ-
ent from the prevalence in our study.
In the French cohort, the description
of intracranial abnormalities is based
on patients’ physician reports and not
on dedicated evaluation of brain MR
imaging by a neuroradiologist. Be-
cause a DVA may be considered a nor-
mal variant, its mention may be omit-
ted from radiology reports; this may
explain the discrepancy. Most studies
describing patients with CMMRD are
dedicated to the clinical course and
genetics; we did not find, to date, an
additional description of associated intracranial vascular
malformations.
In a child with a tumor, clinical suspicion of CMMRD arises
when coexistence of several features is observed. These include a
consanguineous family, café au-lait spots (possibly mimicking
neurofibromatosis type 1), and a family history of malignancies in
young relatives, especially brain tumors, lymphomas, or leuke-
mias. Indeed, these and additional clinical manifestations were
recently suggested to serve as criteria for a clinical diagnosis of
CMMRD.1 Our data suggest that the presence of multiple DVAs
in an MR imaging of the brain with an associated brain tumor or
other CMMRD-related malignancy can be another clue to the
diagnosis. This marker can be especially helpful to determine the
clinical diagnosis of CMMRD in individuals who are unaffected
by cancer and in whom the genetic tests are inconclusive. Most
interesting, in 2 patients, in whom there was clinical suspicion of
CMMRD, the lack of DVAs was associated with negative molec-
ular evidence of CMMRD (unpublished data).
The main limitation of this study is the small group of patients.
FIG 1. Coronal T1-weighted postgadolinium injection images (A and B) demonstrate 3 prominent
DVAs (arrows) in a girl who is homozygote for the PMS2 mutation.
FIG 2. MR imaging study of a boy who is homozygote for the PMS2 mutation and has 2 DVAs
demonstrates increased T2 signal in the left frontal white matter on axial T2WI (A). This is asso-
ciated with a subtle DVA (arrow) depicted in the axial T1WI postgadolinium injection (B).
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Further assessment of larger patient cohorts from the interna-
tional consortia will further delineate the exact prevalence of
DVAs and the characteristics of DVAs in this patient population.
However, the presence of multiple DVAs in all patients in this
study has no parallel description in any other pathology, support-
ing the important role of DVAs for the clinical diagnosis of
CMMRD.
CONCLUSIONS
Our cohort had 100% prevalence of multiple CNS DVAs in pa-
tients with CMMRD. If confirmed, this quantifiable feature can
be added to the current scoring system and result in early imple-
mentation of genetic testing and surveillance protocols, which can
be life-saving for these patients and families as well as allowing
targeted tumor management.20,21
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